Clinical trial NCT03789149: Focal Intraoperative Radiotherapy of Brain Metastases
Official title: Focal Intraoperative Radiotherapy After Resection of Brain Metastases
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Brain Metastases, Adult
Central Nervous System Metastases
Keywords: Intraoperative Radiotherapy
Lead sponsor: AC Camargo Cancer Center
Sponsor class: OTHER
Collaborators: name: Carl Zeiss Meditec AG
First posted: 2018-12-28
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single group assignment
Primary purpose: TREATMENT

Brief summary: Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM. In this context, intraoperative radiotherapy (IORT) in the cavity after resection of BM may be an appealing option.

The primary objectives of this study are to evaluate local control (LC) and the control of brain disease (LC associated with the absence of new distant BM) after IORT for one completely resected supratentorial BM in the presence of up to 10 lesions suggestive of BM.

Detailed description: Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. This type of metastasis occurs in 20-40% of cancer patients and are related to significant morbidity and mortality.

In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM.

The utilization of intraoperative radiotherapy (IORT) in the cavity after resection of primary or BM has been described in the literature, the majority of reports describes performing brachytherapy with iodine seeds or interstitial radiosurgery. However, there is a paucity of information regarding the use of IORT with low energy X-ray for focal treatment after resection of brain BM.

The objectives of this study are evaluate local control (LC), the control of brain disease in patients with metastatic brain disease (up to 10 lesions) submitted to focal IORT to an isolated surgical cavity, evaluate overall survival (OS), evaluate the frequency of radiation necrosis and correlate the prognostic factors related to the patient with OS and the parameters of the treatment (dose, volume, lesion location) with the LC and radiation necrosis.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Histologically confirmed diagnosis of invasive cancer in the presence of up to 10 lesions suggestive of BM
* Indication of resection of single lesion suggestive of BM and evidence of macroscopic complete resection
* Patient consent to participate in the study

Exclusion Criteria:

* Previous cranial radiotherapy
* Any kind of antineoplasic systemic treatment for less than 7 days of the procedure
* Cavities with proximity \< 10 mm from the brainstem or optical pathway.
* Pregnant patients

Primary outcomes:
measure: Local control (LC)
timeFrame: 1 year
measure: Control of Brain Disease (CBD)
timeFrame: 1 year
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: 1 year
measure: Frequency of radiation necrosis
timeFrame: 1 year
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: AC Camargo Cancer Center
state: SP
Study officials:
affiliation: AC Camargo Cancer Center
name: Douglas G Castro, MD
role: PRINCIPAL_INVESTIGATOR
References: